Agile Therapeutics Inc (NASDAQ:AGRX)‘s stock had its “buy” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued on Monday, May 8th. They presently have a $9.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 167.06% from the stock’s current price.
The analysts wrote, “Undervalued Asset: Following the January results of the Phase 3 SECURE trial, shares have struggled. Following two KOL calls discussed in our April note, however, we continue to believe that AGRX has delivered on what the FDA had previously asked of them following the original CRL and that TWIRLA is an approvable product.””
Several other research firms have also commented on AGRX. Zacks Investment Research lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 13th. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Monday, March 13th. FBR & Co set a $10.00 target price on shares of Agile Therapeutics and gave the company a “buy” rating in a report on Saturday, March 11th. Finally, Royal Bank of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the company a “buy” rating in a research note on Friday, January 27th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.92.
Shares of Agile Therapeutics (NASDAQ:AGRX) traded down 1.17% during mid-day trading on Monday, reaching $3.37. The company had a trading volume of 82,340 shares. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.65. The stock’s market capitalization is $97.08 million. The company’s 50-day moving average is $3.25 and its 200 day moving average is $4.05.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Wednesday, March 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. Analysts anticipate that Agile Therapeutics will post ($1.10) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/05/19/agile-therapeutics-inc-agrx-given-buy-rating-at-cantor-fitzgerald-updated.html.
In other news, insider Renee Selman purchased 53,333 shares of the stock in a transaction on Thursday, May 11th. The stock was purchased at an average price of $3.68 per share, for a total transaction of $196,265.44. Following the acquisition, the insider now owns 53,333 shares in the company, valued at $196,265.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Alfred Altomari purchased 10,000 shares of the stock in a transaction on Thursday, May 11th. The shares were purchased at an average price of $3.51 per share, with a total value of $35,100.00. Following the acquisition, the chairman now owns 151,587 shares in the company, valued at approximately $532,070.37. The disclosure for this purchase can be found here. 3.50% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in AGRX. Royce & Associates LP raised its stake in shares of Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock worth $3,165,000 after buying an additional 665,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Agile Therapeutics by 79.8% in the first quarter. Vanguard Group Inc. now owns 801,114 shares of the specialty pharmaceutical company’s stock worth $2,568,000 after buying an additional 355,535 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Agile Therapeutics during the fourth quarter worth approximately $3,770,000. Deerfield Management Co. increased its position in Agile Therapeutics by 59.2% in the fourth quarter. Deerfield Management Co. now owns 398,000 shares of the specialty pharmaceutical company’s stock worth $2,269,000 after buying an additional 148,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Agile Therapeutics by 72.0% in the first quarter. Geode Capital Management LLC now owns 201,152 shares of the specialty pharmaceutical company’s stock worth $644,000 after buying an additional 84,212 shares in the last quarter. Institutional investors own 83.55% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.